Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 68

Results For "low"

3901 News Found

FDA nod to first oral single-dose treatment for gonorrhea
Drug Approval | December 16, 2025

FDA nod to first oral single-dose treatment for gonorrhea

The approval of Nuzolvence (zoliflodacin) follows a collaborative development effort with the Global Antibiotic Research and Development Partnership


Sanofi secures two breakthrough nods in China for rare blood disorders
News | December 16, 2025

Sanofi secures two breakthrough nods in China for rare blood disorders

Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia


Accenture invests in Ryght AI to revolutionize clinical trials
Digitisation | December 16, 2025

Accenture invests in Ryght AI to revolutionize clinical trials

Ryght AI tackles these hurdles with its AI Site Twin platform


Ind-Swift Laboratories receives GMP compliance certificate from NNGYK-Hungary
News | December 16, 2025

Ind-Swift Laboratories receives GMP compliance certificate from NNGYK-Hungary

The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products


Pharma overhaul: EMA hails “Once-in-a-Generation” reform
Policy | December 16, 2025

Pharma overhaul: EMA hails “Once-in-a-Generation” reform

The reform is set to modernise how medicines are developed, authorised, and made available across the EU


Neuren partner Acadia bags FDA go-ahead for new DAYBUE STIX powder for Rett Syndrome
Drug Approval | December 16, 2025

Neuren partner Acadia bags FDA go-ahead for new DAYBUE STIX powder for Rett Syndrome

The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste


Sobi to acquire Arthrosi Therapeutics in $950 million deal, bolstering gout pipeline
Clinical Trials | December 16, 2025

Sobi to acquire Arthrosi Therapeutics in $950 million deal, bolstering gout pipeline

The drug is currently being evaluated in two fully recruited global Phase 3 studies for progressive and tophaceous gout, with results expected in 2026.


Anova launches AI-powered patient matching platform to speed clinical trial enrollment
News | December 16, 2025

Anova launches AI-powered patient matching platform to speed clinical trial enrollment

Clinical trial enrollment has long been a bottleneck in drug development